ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
주요 하이라이트
헤파린 유발 혈소판 감소증 시장 규모는 2023년 약 1억 2,800만 달러에 달할 것으로 추정됩니다.
헤파린 유발 혈소판 감소증은 헤파린 치료 시작 후 5-14일째에 혈소판 수가 급격히 감소하는 것이 특징입니다. 이는 주로 혈소판 4인자(PF4)와 헤파린에 대한 항체 형성에 의해 발생합니다.
헤파린 유발성 혈소판 감소증의 진단은 임상 평가, 임상 검사, 4Ts 채점 시스템의 조합에 따라 이루어집니다. 임상 검사에는 혈소판 수 측정, 항-PF4/헤파린 항체 검출, 혈소판 활성화를 평가하는 기능적 분석 등이 포함됩니다.
헤파린으로 인한 혈소판 감소증을 관리하기 위해서는 모든 형태의 헤파린을 즉시 중단하고 직접 트롬빈 억제제(예: 알가트로반, 비바리루딘) 또는 제 Xa 인자 억제제(예: 폰다팔리넥스, 다나파로이드)와 같은 비헤파린계 항응고제 투여를 시작해야 합니다. 투여를 시작해야 합니다. 비헤파린계 항응고제로 전환하는 동안 혈소판 수치, 혈전증 임상 증상, 출혈성 합병증에 대한 면밀한 모니터링이 필수적입니다.
주요 7개국에서 알가트로반은 2023년 6,200만 달러로 가장 큰 시장 점유율을 차지했습니다.
헤파린 유발 혈소판 감소증 치료제로 단일 요법인 VLX-1005(Veralox Therapeutics)가 연구되고 있으며, 2022년 6월, VLX-1005는 양호한 임상 1상 결과를 바탕으로 FDA로부터 패스트트랙 지정을 받았습니다.
2023년에는 약 22,800건의 헤파린 유발성 혈소판 감소증으로 진단된 우발적 사례가 기록될 것으로 예상됩니다. 주요 7개국 중 미국이 진단된 환자 수에서 가장 큰 점유율을 차지하며 전체의 약 51%를 차지할 것으로 예상됩니다.
EU 4개국 및 영국에서는 독일이 헤파린 유발 혈소판감소증 환자 수가 가장 많으며, 프랑스가 전체 환자 수의 약 23%를 차지합니다.
2023년 미국 내 헤파린 노출 유형별 헤파린 유발 혈소판감소증 환자 수는 미분획 헤파린(UFH)의 경우 약 107,000명, 저분자량 헤파린(LMWH)의 경우 약 6,000명으로 추산됩니다.
헤파린 유발 혈소판 감소증 보고서 개요
이 보고서는 역학 부문과 예측에 대한 광범위한 지식을 제공하고, 진단율, 질병 진행, 치료 가이드라인의 미래 잠재적 성장에 대한 깊은 이해를 제공합니다. 이러한 측면에 대한 종합적인 통찰력을 제공하여 주제에 대한 철저한 평가를 가능하게 합니다.
또한, 현재 관리 기술과 새로운 치료법에 대한 종합적인 설명과 현재 치료 상황에 영향을 미치고 전반적인 시장 변화에 영향을 미칠 수 있는 후기(Phase II) 및 저명한 치료법에 대한 상세한 프로파일이 보고서에 포함되어 있습니다.
헤파린에 의한 혈소판감소증 시장에 대한 종합적인 분석과 과거 및 예측 시장 규모(2020-2034년)에 대한 상세한 검증을 수록했습니다. 또한, 치료제 시장 점유율, 상세한 전제조건, 조사 방법론의 근거도 기술하고 있습니다. 또한, 주요 7개국 지역에서의 약품의 아웃리치도 수록되어 있습니다.
이 보고서에는 SWOT 분석, 다양한 병원 및 유명 대학 전문가를 포함한 전문가 통찰력/KOL의 견해, 환자 여정, 주요 7개국 헤파린 유발성 혈소판 감소증 시장 형성 및 촉진에 도움이 되는 치료 선호도 등의 동향을 이해함으로써 사업 전략을 수립하는 데 도움이 되는 질적 통찰력이 포함되어 있습니다.
헤파린 유발성 혈소판 감소증은 일반적으로 사용되는 항응고제인 헤파린의 투여로 인해 발생하는 심각하고 생명을 위협할 수 있는 면역 매개성 부작용입니다. 헤파린 유발 혈소판 감소증은 헤파린 치료 시작 후 5-14일째에 혈소판 수가 급격히 감소하는 것이 특징입니다. 이는 주로 혈소판 4인자(PF4)와 헤파린의 복합체에 대한 항체 형성에 의해 발생합니다. 이러한 항체는 혈소판 활성화를 유도하여 혈전 촉진 상태와 정맥 및 동맥 혈전증 위험 증가를 초래합니다.
미분획 헤파린(UFH)과 저분자 헤파린(LMWH)의 두 가지 유형이 널리 사용되고 있으며, LMWH는 고분자 헤파린을 분획하여 얻은 단쇄 다당류로 구성되어 있습니다. 혈소판 응집 시간(aPTT)을 모니터링할 필요가 없고, 헤파린으로 인한 혈소판 감소증의 위험이 낮다는 점 등 여러 가지 면에서 차이가 있습니다. 또한, 헤파린의 항응고 효과는 황산 프로타민으로 가역적인 반면, LMWH의 효과는 제한적입니다.
헤파린 유발 혈소판 감소증의 신속하고 확실한 진단은 어렵고 가장 중요합니다. 헤파린 유발성 혈소판 감소증의 진단 기준은 다음과 같습니다:
헤파린 투여 시작 전 혈소판 수는 정상입니다.
혈소판감소증이란 혈소판 수가 30% 감소하여 100X 109/L
미만인 경우, 또는 혈소판 수가 기준치 대비 50% 이상 감소된 경우
혈소판 감소의 다른 원인 배제
헤파린 투여 중단 후 혈소판 감소 소실
헤파린에 의한 혈소판 감소 항체 혈청 전환
일반적인 치료법으로는 직접 비경구용 트롬빈 억제제(알가트로반, 데시루딘, 비바리루딘)와 간접 비경구용 제 Xa인자 억제제(다나파로이드 또는 폰다팔리눅스)가 있습니다. 직접 경구용 항응고제(DOACs)는 최근 급성 헤파린 유발 혈소판 감소증과 혈전증을 동반한 헤파린 유발 혈소판 감소증에 대한 대안으로 떠오르고 있습니다. 추가 혈전증을 예방하는 것은 필수적입니다. 따라서 헤파린을 예방적 목적으로만 투여하더라도 환자는 일반적으로 다른 항응고제로 치료받게 됩니다.
와파린은 반감기가 짧은 단백질 C와 S를 억제하여 초기에는 응고항진 상태가 되므로 단기적으로는 사용하지 않는 것이 좋습니다. 헤파린 유발성 혈소판 감소증 진단 시 환자가 와파린을 복용하고 있다면 비타민 K를 통한 역치료가 권장됩니다. 직접 경구용 항응고제는 와파린에 비해 식이 제한이 적고 약물 상호 작용이 적으며 특별한 모니터링이 필요하지 않기 때문에 직접 경구용 항응고제는 와파린보다 더 간단한 치료 옵션으로 간주됩니다.
Veralox Therapeutics, Sandoz, Fresenius Kabi, Hikma Pharm 등 다양한 주요 기업들이 헤파린 유발 혈소판감소증 치료제 시장을 주도하고 있습니다. 국가별 및 치료제별 시장 규모는 다음과 같습니다.
주요 7개국 헤파린 유발 혈소판 감소증 시장은 2023년 약 1억 2,800만 달러에 달할 것으로 추정됩니다.
미국은 주요 7개국 전체 시장의 약 50%를 차지하고 있습니다.
2023년에는 EU 4개국 및 영국 중 독일이 가장 큰 시장 점유율을 차지하며 전체 시장의 약 40%를 차지했습니다.
2023년 일본은 시장 규모에 약 300만 달러에 기여할 것이며, 2034년까지 안정적인 성장을 보일 것으로 예상됩니다.
세계 주요 7개국 헤파린 유발성 혈소판감소증 시장에 대해 조사했으며, 시장 개요, 역학, 환자 동향, 새로운 치료법, 2034년까지 시장 규모 예측, 미충족 의료 수요 등을 조사하여 전해드립니다.
목차
제1장 주요 인사이트
제2장 보고서 서론
제3장 헤파린 유발 혈소판 감소증(HIT) 시장 개요
2020년 헤파린 유발 혈소판 감소증(HIT) 국가별 시장 점유율(%)
2034년 헤파린 유발 혈소판 감소증(HIT) 국가별 시장 점유율(%)
2020년 헤파린 유발 혈소판 감소증(HIT) 치료법별 시장 점유율(%)
2034년 헤파린 유발 혈소판 감소증(HIT) 치료법별 시장 점유율(%)
제4장 헤파린 유발 혈소판 감소증(HIT) 주요 요약
제5장 주요 이벤트
제6장 질환 배경과 개요
의약품으로서의 헤파린과 헤파린 다양한 형태
HIT의 유형
징후와 증상
리스크 요인
헤파린 유발 혈소판 감소증(HIT)의 병태생리학
헤파린 유발 혈소판 감소증의 임상 증상과 합병증
헤파린 유발 혈소판 감소증 진단
진단 가이드라인
제7장 헤파린 유발 혈소판 감소증 치료
대체 항응고요법
응고 대체제 및 보조제
치료 가이드라인
제8장 조사 방법
제9장 헤파린 유발 혈소판 감소증 역학과 환자 인구
주요 조사 결과
가정과 근거
주요 7개국의 헤파린 유발 혈소판 감소증(HIT) 발병 건수
미국
EU 4개국 및 영국
일본
제10장 헤파린 유발 혈소판 감소증 환자 동향
제11장 헤파린 유발 혈소판 감소증 출시 약제
ANGIOMAX (bivalirudin): Sandoz
Argatroban: Sandoz/Fresenius Kabi/Hikma Pharm
제12장 헤파린 유발 혈소판 감소증 새로운 치료법
주요 교차 경쟁 : 신흥 치료법
VLX-1005 : Veralox Therapeutics
제13장 헤파린 유발 혈소판 감소증(HIT) : 주요 7개국 시장 분석
주요 조사 결과
시장 전망
주요 시장 예측의 전제조건
주요 시장 예측의 전제조건
주요 7개국의 헤파린 유발 혈소판 감소증(HIT) 전체 시장 규모
주요 7개국의 헤파린 유발 혈소판 감소증(HIT) 시장 규모(치료법별)
미국 시장 규모
EU 4개국 및 영국
일본 시장 규모
제14장 KOL(Key Opinion Leader)의 견해
제15장 SWOT 분석
제16장 헤파린 유발 혈소판 감소증의 미충족 요구
제17장 시장 접근과 상환
미국
EU 4개국 및 영국
일본
제18장 부록
제19장 DelveInsight의 서비스 내용
제20장 면책사항
LSH
영문 목차
영문목차
Key Highlights:
The heparin-induced thrombocytopenia market size in the 7MM is estimated to be around ~USD 128 million, in 2023.
Heparin-induced thrombocytopenia is characterized by a rapid decrease in platelet count occurring 5-14 days after the initiation of heparin therapy. It is primarily caused by the formation of antibodies against platelet factor 4 (PF4) and heparin.
The diagnosis of Heparin-induced thrombocytopenia is based on a combination of clinical assessment, laboratory tests, and the 4Ts scoring system. Laboratory tests include measuring platelet count, detecting anti-PF4/heparin antibodies, and functional assays to assess platelet activation.
The management of Heparin-induced thrombocytopenia involves immediate discontinuation of all forms of heparin and initiation of alternative non-heparin anticoagulants, such as direct thrombin inhibitors (e.g., argatroban, bivalirudin) or factor Xa inhibitors (e.g., fondaparinux, danaparoid). Close monitoring of platelet counts, clinical signs of thrombosis, and bleeding complications is essential during the transition to non-heparin anticoagulation.
In the 7MM, Argatroban accounted for the largest market share of ~USD 62 million in 2023.
A single therapy, VLX-1005 (Veralox Therapeutics), is being investigated for treating Heparin-induced thrombocytopenia. In June 2022, VLX-1005 received fast track designation from the FDA, based on the positive Phase I results.
In 2023, approximately 220,800 diagnosed incident cases of Heparin-induced thrombocytopenia were recorded. Among the 7MM, the United States holds the largest share of diagnosed incident cases, making up around 51% of the total cases.
Among EU4 and the UK, Germany recorded highest incident cases of Heparin-induced thrombocytopenia, followed by France, contributing approximately 23% of the total incident cases.
In 2023, the total incident cases of Heparin-induced thrombocytopenia in type-specific heparin exposure in the US were estimated to be ~107,000 and ~6,000 cases for unfractionated heparin (UFH) and low molecular-weight heparin (LMWH), respectively.
Heparin-induced Thrombocytopenia Report Summary
The report offers extensive knowledge regarding the epidemiology segments and predictions, presenting a deep understanding of the potential future growth in diagnosis rates, disease progression, and treatment guidelines. It provides comprehensive insights into these aspects, enabling a thorough assessment of the subject matter.
Additionally, an all-inclusive account of the current management techniques and emerging therapies and the elaborative profiles of late-stage (Phase II) and prominent therapies that would impact the current treatment landscape and result in an overall market shift has been provided in the report.
The report also encompasses a comprehensive analysis of the Heparin-induced thrombocytopenia market, providing an in-depth examination of its historical and projected market size (2020 - 2034). It also includes the market share of therapies, detailed assumptions, and the underlying rationale for our methodology. The report also includes drug outreach coverage in the 7MM region.
The report includes qualitative insights that provide an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, including experts from various hospitals and prominent universities, patient journey, and treatment preferences that help shape and drive the 7MM Heparin-induced thrombocytopenia market.
Heparin-induced Thrombocytopenia Treatment Market
Heparin-induced Thrombocytopenia Overview
Heparin-induced thrombocytopenia is a severe and potentially life-threatening immune-mediated adverse reaction triggered by the administration of heparin, a commonly used anticoagulant medication. Heparin-induced thrombocytopenia is characterized by a rapid decrease in platelet count occurring 5-14 days after the initiation of heparin therapy. It is primarily caused by the formation of antibodies against the complex of platelet factor 4 (PF4) and heparin. These antibodies induce platelet activation, leading to a prothrombotic state and an increased venous and arterial thrombosis risk.
Two forms of heparin are widely used: unfractionated heparin (UFH) and low molecular weight heparin (LMWH). LMWH consists of only short chains of the polysaccharide, and is obtained by fractionation of polymeric heparin. LMWH differs from unfractionated heparin in a number of ways, including the need for only once or twice daily dosing; the absence of monitoring the activated partial thromboplastin time (aPTT); and the lower risk of Heparin-induced thrombocytopenia. In addition, the anticoagulant effect of heparin is reversible with protamine sulfate, whereas its effect on LMWH is limited.
Heparin-induced Thrombocytopenia Diagnosis
Making a rapid and confirmed diagnosis of Heparin-induced thrombocytopenia is challenging and of utmost importance. The criteria for diagnosis of Heparin-induced thrombocytopenia include:
Normal platelet count before the commencement of heparin
Thrombocytopenia is defined as a drop in platelet count by 30% to <100 X 109/L or a drop of >50% from the patient's baseline platelet count
The onset of thrombocytopenia typically 5-10 days after initiation of heparin treatment, which can occur earlier with previous heparin exposure (within 100 days)
Acute thrombotic event
The exclusion of other causes of thrombocytopenia
The resolution of thrombocytopenia after cessation of heparin
Common treatment modalities include direct parenteral thrombin inhibitors (argatroban, Desirudin, or bivalirudin) and indirect parenteral factor Xa inhibitors (danaparoid or fondaparinux). Direct oral anticoagulants (DOACs) are recently emerging as an alternative in acute Heparin-induced thrombocytopenia or Heparin-induced thrombocytopenia with thrombosis. It is essential to prevent additional thrombosis. Therefore, patients are usually treated with an alternative anticoagulant, even if heparin was given only as a prophylactic measure.
Warfarin is avoided in the short term due to its initial hypercoagulable state via inhibition of proteins C and S, which have short half-lives. If the patient was on warfarin during Heparin-induced thrombocytopenia diagnosis, reversal with vitamin K is recommended. Compared with warfarin, direct oral anticoagulants have fewer dietary restrictions, a lower number of drug-drug interactions, and do not require specific monitoring; thus, direct oral anticoagulants are considered a more convenient treatment option than warfarin.
Heparin-induced Thrombocytopenia Market
Various key players are leading the treatment landscape of Heparin-induced thrombocytopenia, such as like Veralox Therapeutics, Sandoz, Fresenius Kabi, Hikma Pharm and others. The details of the country-wise and therapy-wise market size have been provided below.
The market of heparin-induced thrombocytopenia in the 7MM is estimated to be around ~USD 128 million, in 2023.
The United States comprised roughly 50% of the overall market within the 7MM
In 2023, among the EU4 and the UK, Germany held the largest market share, comprising approximately 40% of the total market size.
In 2023, Japan contributed approximately ~USD 3 million to the market size, with expectations of steady growth projected until 2034.
Heparin-induced Thrombocytopenia Drug Chapters
The section dedicated to drugs in the Heparin-induced thrombocytopenia report provides an in-depth evaluation of late-stage pipeline drugs (Phase II) related to Heparin-induced thrombocytopenia.
The drug chapters section provides valuable information on various aspects related to clinical trials of Heparin-induced thrombocytopenia, such as the pharmacological mechanisms of the drugs involved, designations, approval status, patent information, and a comprehensive analysis of the pros and cons associated with each drug. Furthermore, it presents the most recent news updates and press releases on drugs targeting Heparin-induced thrombocytopenia
Bivalirudin is an inhibitor of thrombin, an essential factor within the coagulation cascade crucial to thrombus formation, and is used as an anticoagulant. Bivalirudin reversibly binds thrombin, free as well as clot bound, at the catalytic site and the anion-binding exosite, thereby preventing the formation and activation of fibrin, Factor XIIIa, and other coagulation factors. Administered intravenously, Bivalirudin is indicated for use in patients undergoing percutaneous coronary intervention (PCI), including patients with Heparin-induced thrombocytopenia or heparin-induced thrombocytopenia and thrombosis syndrome (Heparin-induced thrombocytopeniaTS). Its short duration of effect makes it convenient for those with bleeding risks or undergoing additional procedural interventions and needing a rapid cessation of drug effect.
Argatroban: Sandoz/Fresenius Kabi/Hikma Pharm
Argatroban, a small molecule, is a synthetic direct thrombin inhibitor. It is an anticoagulant in individuals with thrombosis and heparin-induced thrombocytopenia. It reversibly binds to the catalytic site of thrombin and directly and reversibly blocks its ability to activate clotting Factors V, VIII, and XII. Argatroban is given intravenously, metabolized in the liver, and has a half-life of about 50 min. Because of its hepatic metabolism, it may be used in patients with renal dysfunction.
VLX-1005 is a first-in-class and selective small molecule inhibitor 12-lipoxygenase, a key target within the arachidonic acid pathway. It blocks the 12-LOX pathway responsible for platelet activation in Heparin-induced thrombocytopenia. It is administered through the IV and oral route; preclinical data has demonstrated that VLX-1005 halts the immune-driven platelet activation and thrombosis, thus offering the potential of lifesaving treatment for patients with Heparin-induced thrombocytopenia.
This drug is being studied in a Phase II (NCT05785819) trial to evaluate its efficacy and safety in treating Heparin-induced thrombocytopenia.
In June 2023, Veralox Therapeutics announced the appointment of Jonathan Mow as the company's new chief executive officer. Mr. Mow's appointment came as Veralox secured USD 24 million in funding to advance VLX-1005 through a Phase IIa proof-of-concept study evaluating its impact on Heparin-induced thrombocytopenia.
Heparin-induced Thrombocytopenia Market Outlook
The primary treatment approach involves discontinuing unfractionated heparin (UFH) or low molecular-weight heparin (LMWH) in patients suspected of or diagnosed with Heparin-induced thrombocytopenia, and initiating therapy with an alternative anticoagulant. LMWH is not an appropriate alternative if Heparin-induced thrombocytopenia develops during treatment with UFH because of cross-reactivity. Argatroban and bivalirudin are both non-cross reacting. Danaparoid demonstrates cross reactivity, which is rarely observed in vivo while fondaparinux is highly immunogenic but is not well recognized by anti-fondaparinux-PF4 antibodies generated during exposure, suggesting that it should be associated with a low risk of developing Heparin-induced thrombocytopenia. Warfarin, especially when used in isolation, can increase the risk of microvascular thrombosis in Heparin-induced thrombocytopenia and its introduction should be delayed until there has been substantial resolution of the thrombocytopenia.
Several novel oral anticoagulants also exist (e.g. rivaroxaban,dabigatran,apixaban), and preliminary evidence suggests that they may be beneficial for Heparin-induced thrombocytopenia, particularly in cases refractory to standard therapies. However, these agents have not been fully assessed for treatment of patients with Heparin-induced thrombocytopenia and none have FDA approval for use in Heparin-induced thrombocytopenia
In conclusion, despite the lack of appropriate treatment in the current treatment landscape, many potential therapies with novel mechanisms are expected to enter the market, resolving a dire unmet need and leading to significant improvement in the treatment outcome of Heparin-induced thrombocytopenia patients. Hence, with the upcoming availability of new treatment options and increasing healthcare spending across the 7MM, the treatment scenario is expected to experience significant growth during the forecast period (2024-2034).
Heparin-induced Thrombocytopenia Epidemiology
The Heparin-induced thrombocytopenia epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases, type-specific Cases, Age-specific Cases, total cases of Heparin-induced thrombocytopenia in the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2020 to 2034.
In 2023, the total incident cases of Heparin Induced Thrombocytopenia (Heparin-induced thrombocytopenia) in type-specific heparin exposure in the US were estimated to be ~107,000 and ~6,000 cases for UFW and LMWH.
In 2023, Germany accounted for approximately 38% of the total incident Heparin-induced thrombocytopenia cases, among EU4 and the UK.
In 2023, there were ~1,500, ~27,800, and ~84,000 cases of Heparin Induced Thrombocytopenia (Heparin-induced thrombocytopenia) in the US, in 19 years and below, 20 years to 59 years and 60 years and above, respectively.
In 2023, there were total ~7,700 incident cases of Heparin Induced Thrombocytopenia (Heparin-induced thrombocytopenia), in Japan.
KOL Views
To stay abreast of the latest trends in the market, we conduct primary research by seeking the opinions of Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) who work in the relevant field. This helps us fill any gaps in data and validate our secondary research.
We have reached out to industry experts to gather insights on various aspects of Heparin-induced thrombocytopenia, including the evolving treatment landscape, patients' reliance on conventional therapies, their acceptance of therapy switching, drug uptake, and challenges related to accessibility. The experts we contacted included medical/scientific writers, professors, and researchers from prestigious universities in the US, Europe, the UK, and Japan.
Our team of analysts at Delveinsight connected with more than 15 KOLs across the 7MM. We contacted institutions such as the Division of Hematology and Laboratory of Hematology, Department of Clinical Laboratory Medicine, Stanford University School of Medicine, etc., among others. By obtaining the opinions of these experts, we gained a better understanding of the current and emerging treatment patterns in the Heparin-induced thrombocytopenia market, which will assist our clients in analyzing the overall epidemiology and market scenario.
We perform Qualitative and Market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.
Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, designation, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.
Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, a final weightage score is decided, based on which the emerging therapies are ranked.
Heparin-induced Thrombocytopenia Market Access and Reimbursement
Because newly authorized drugs are often expensive, some patients escape receiving proper treatment or use off-label, less expensive prescriptions. Reimbursement plays a critical role in how innovative treatments can enter the market. The cost of the medicine, compared to the benefit it provides to patients who are being treated, sometimes determines whether or not it will be reimbursed. Regulatory status, target population size, the setting of treatment, unmet needs, the number of incremental benefit claims, and prices can all affect market access and reimbursement possibilities.
The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.
Heparin-induced Thrombocytopenia Report Insights
Heparin-induced Thrombocytopenia Patient Population
Key Questions for Heparin-induced Thrombocytopenia Market
Would there be any changes observed in the current treatment approach?
Will there be any improvements in Heparin-induced thrombocytopenia management recommendations?
Would research and development advances pave the way for future tests and therapies for Heparin-induced thrombocytopenia?
Would the diagnostic testing space experience a significant impact and lead to a positive shift in the treatment landscape of Heparin-induced thrombocytopenia?
What kind of uptake will the new therapies witness in coming years in Heparin-induced thrombocytopenia patients?
Table of Contents
1. Key Insights
2. Report Introduction
3. Heparin-induced Thrombocytopenia (HIT) Market Overview at a Glance
3.1. Market Share (%) Distribution of Heparin-induced Thrombocytopenia (HIT) by Countries in 2020
3.2. Market Share (%) Distribution of Heparin-induced Thrombocytopenia (HIT) by Countries in 2034
3.3. Market Share (%) Distribution of Heparin-induced Thrombocytopenia (HIT) by Therapies in 2020
3.4. Market Share (%) Distribution of Heparin-induced Thrombocytopenia (HIT) by Therapies in 2034
4. Executive Summary of Heparin-induced Thrombocytopenia (HIT)
5. Key Events
6. Disease Background and Overview
6.1. Heparin as a Medication and Different Forms of Heparin
6.2. Types of HIT
6.2.1. HIT Type I
6.2.2. HIT Type II
6.3. Signs and Symptoms
6.4. Risk Factors
6.5. Pathophysiology of Heparin-induced Thrombocytopenia (HIT)
6.5.3. Antigen Formation on the Platelet Surface and Platelet Activation
6.5.4. Other Cells Beyond Platelets Involved in HIT Prothrombotic State
6.6. Clinical Presentation and Complications of Heparin-induced Thrombocytopenia
6.7. Diagnosis of Heparin-induced Thrombocytopenia
6.7.1. Clinical Diagnosis
6.7.2. Laboratory Diagnosis
6.7.3. Differential Diagnosis
6.7.4. Diagnostic Algorithm
6.8. Diagnostic Guidelines
6.8.1. Guidelines on the Diagnosis of HIT: Second Edition
7. Treatment of Heparin-induced Thrombocytopenia
7.1. Alternative Anticoagulation
7.1.1. Argatroban
7.1.2. Bivalirudin
7.1.3. Desirudin
7.1.4. Fondaparinux
7.1.5. Danaparoid
7.1.6. Direct Oral Anticoagulants
7.1.7. Vitamin K Antagonists
7.2. Alternatives and Adjuvants to Coagulation
7.2.1. Therapeutic Plasmapheresis (TPE)
7.2.2. Intravenous Immunoglobulin (IVIG)
7.3. Treatment Guidelines
7.3.1. American Society of Hematology Guidelines for Management of Venous Thromboembolism: Heparin-induced Thrombocytopenia
7.3.2. Guidelines on the Diagnosis and Management of Heparin-induced Thrombocytopenia: Second Edition
7.3.3. American College of Chest Physicians Evidence-based Clinical Practice Guidelines on Treatment and Prevention of Heparin-induced Thrombocytopenia
7.3.4. Japanese Journal of Thrombosis and Hemostasis: Diagnosis and Treatment Guidelines for Heparin-induced Thrombocytopenia
8. Methodology
9. Heparin-induced Thrombocytopenia Epidemiology and Patient Population
9.1. Key Findings
9.2. Assumptions and Rationale
9.3. Total Incident Cases of Heparin-induced Thrombocytopenia (HIT) in the 7MM
9.4. The United States
9.4.1. Total Incident Cases of Heparin-induced Thrombocytopenia (HIT) in the United States
9.4.2. Total Incident Cases of Heparin-induced Thrombocytopenia (HIT) in Type-specific Heparin Exposure in the United States
9.4.3. Age-Specific Cases of Heparin-induced Thrombocytopenia (HIT) in the United States
9.4.4. Total Cases of Thrombosis in Heparin-induced Thrombocytopenia (HIT) in the United States
9.5. EU4 and the UK
9.5.1. Total Incident Cases of Heparin-induced Thrombocytopenia (HIT) in EU4 and the UK
9.5.2. Total Incident Cases of Heparin-induced Thrombocytopenia (HIT) in Type-specific Heparin Exposure in EU4 and the UK
9.5.3. Age-specific Cases of Heparin-induced Thrombocytopenia (HIT) in EU4 and the UK
9.5.4. Total Cases of Thrombosis in Heparin-induced Thrombocytopenia (HIT) in EU4 and the UK
9.6. Japan
9.6.1. Total Incident Cases of Heparin-induced Thrombocytopenia (HIT) in Japan
9.6.2. Total Incident Cases of Heparin-induced Thrombocytopenia (HIT) in Type-specific Heparin Exposure in Japan
9.6.3. Age-specific Cases of Heparin-induced Thrombocytopenia (HIT) in Japan
9.6.4. Total Cases of Thrombosis in Heparin-induced Thrombocytopenia (HIT) in Japan
